JP2020526575A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020526575A5 JP2020526575A5 JP2020519196A JP2020519196A JP2020526575A5 JP 2020526575 A5 JP2020526575 A5 JP 2020526575A5 JP 2020519196 A JP2020519196 A JP 2020519196A JP 2020519196 A JP2020519196 A JP 2020519196A JP 2020526575 A5 JP2020526575 A5 JP 2020526575A5
- Authority
- JP
- Japan
- Prior art keywords
- migraine
- leucine
- pharmaceutical composition
- acceptable salt
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 claims description 133
- 229960000669 acetylleucine Drugs 0.000 claims description 69
- WXNXCEHXYPACJF-ZETCQYMHSA-N N-acetyl-L-leucine Chemical compound CC(C)C[C@@H](C(O)=O)NC(C)=O WXNXCEHXYPACJF-ZETCQYMHSA-N 0.000 claims description 68
- 206010027599 migraine Diseases 0.000 claims description 49
- 208000019695 Migraine disease Diseases 0.000 claims description 47
- 230000002265 prevention Effects 0.000 claims description 37
- 208000024891 symptom Diseases 0.000 claims description 19
- 239000002243 precursor Substances 0.000 claims description 13
- KRQUFUKTQHISJB-YYADALCUSA-N 2-[(E)-N-[2-(4-chlorophenoxy)propoxy]-C-propylcarbonimidoyl]-3-hydroxy-5-(thian-3-yl)cyclohex-2-en-1-one Chemical compound CCC\C(=N/OCC(C)OC1=CC=C(Cl)C=C1)C1=C(O)CC(CC1=O)C1CCCSC1 KRQUFUKTQHISJB-YYADALCUSA-N 0.000 claims description 10
- 206010019233 Headaches Diseases 0.000 claims description 10
- 231100000869 headache Toxicity 0.000 claims description 10
- 208000002173 dizziness Diseases 0.000 claims description 8
- 206010020751 Hypersensitivity Diseases 0.000 claims description 6
- 206010028813 Nausea Diseases 0.000 claims description 6
- 208000026935 allergic disease Diseases 0.000 claims description 6
- 230000009610 hypersensitivity Effects 0.000 claims description 6
- 230000008693 nausea Effects 0.000 claims description 6
- 230000001720 vestibular Effects 0.000 claims description 5
- 206010003791 Aura Diseases 0.000 claims description 4
- 206010015037 epilepsy Diseases 0.000 claims description 4
- IVWWFWFVSWOTLP-YVZVNANGSA-N (3'as,4r,7'as)-2,2,2',2'-tetramethylspiro[1,3-dioxolane-4,6'-4,7a-dihydro-3ah-[1,3]dioxolo[4,5-c]pyran]-7'-one Chemical compound C([C@@H]1OC(O[C@@H]1C1=O)(C)C)O[C@]21COC(C)(C)O2 IVWWFWFVSWOTLP-YVZVNANGSA-N 0.000 claims description 3
- 208000004998 Abdominal Pain Diseases 0.000 claims description 3
- 208000012639 Balance disease Diseases 0.000 claims description 3
- 206010012735 Diarrhoea Diseases 0.000 claims description 3
- 208000004044 Hypesthesia Diseases 0.000 claims description 3
- 208000016285 Movement disease Diseases 0.000 claims description 3
- 208000002193 Pain Diseases 0.000 claims description 3
- 206010034972 Photosensitivity reaction Diseases 0.000 claims description 3
- 208000003443 Unconsciousness Diseases 0.000 claims description 3
- 206010047571 Visual impairment Diseases 0.000 claims description 3
- 208000034783 hypoesthesia Diseases 0.000 claims description 3
- 231100000862 numbness Toxicity 0.000 claims description 3
- 208000035824 paresthesia Diseases 0.000 claims description 3
- 230000036211 photosensitivity Effects 0.000 claims description 3
- 230000035900 sweating Effects 0.000 claims description 3
- 208000029257 vision disease Diseases 0.000 claims description 3
- 230000000007 visual effect Effects 0.000 claims description 3
- 230000004393 visual impairment Effects 0.000 claims description 3
- 206010050258 Basilar migraine Diseases 0.000 claims description 2
- 208000010541 Familial or sporadic hemiplegic migraine Diseases 0.000 claims description 2
- 206010019476 Hemiplegic migraine Diseases 0.000 claims description 2
- 208000000060 Migraine with aura Diseases 0.000 claims description 2
- 206010052784 Retinal migraine Diseases 0.000 claims description 2
- 206010016256 fatigue Diseases 0.000 claims description 2
- 208000017420 migraine with brainstem aura Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 21
- 206010016326 Feeling cold Diseases 0.000 claims 1
- 208000035238 familial hemiplegic 1 migraine Diseases 0.000 claims 1
- 230000003252 repetitive effect Effects 0.000 claims 1
- 208000006122 sporadic hemiplegic migraine Diseases 0.000 claims 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 65
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 65
- 239000003814 drug Substances 0.000 description 14
- 229940079593 drug Drugs 0.000 description 10
- 238000000034 method Methods 0.000 description 7
- 230000035807 sensation Effects 0.000 description 4
- 208000037048 Prodromal Symptoms Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 238000007913 intrathecal administration Methods 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 206010027603 Migraine headaches Diseases 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1709459.0A GB201709459D0 (en) | 2017-06-14 | 2017-06-14 | Treatment for migraine |
| PCT/IB2018/054676 WO2018229738A1 (en) | 2017-06-14 | 2018-06-25 | Treatment for migraine |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020526575A JP2020526575A (ja) | 2020-08-31 |
| JP2020526575A5 true JP2020526575A5 (enExample) | 2021-08-12 |
| JP7130739B2 JP7130739B2 (ja) | 2022-09-05 |
Family
ID=59358204
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020519196A Active JP7130739B2 (ja) | 2017-06-14 | 2018-06-25 | 片頭痛の治療 |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US11471434B2 (enExample) |
| EP (1) | EP3638370B1 (enExample) |
| JP (1) | JP7130739B2 (enExample) |
| KR (1) | KR102594130B1 (enExample) |
| CN (1) | CN111093772B (enExample) |
| AU (1) | AU2018284330B2 (enExample) |
| CY (1) | CY1123860T1 (enExample) |
| DK (1) | DK3638370T3 (enExample) |
| ES (1) | ES2847169T3 (enExample) |
| GB (1) | GB201709459D0 (enExample) |
| HR (1) | HRP20210108T1 (enExample) |
| HU (1) | HUE053089T2 (enExample) |
| IL (1) | IL271211B2 (enExample) |
| LT (1) | LT3638370T (enExample) |
| MA (1) | MA49396B1 (enExample) |
| MD (1) | MD3638370T2 (enExample) |
| MX (1) | MX387909B (enExample) |
| PL (1) | PL3638370T3 (enExample) |
| PT (1) | PT3638370T (enExample) |
| RS (1) | RS61481B1 (enExample) |
| SG (1) | SG11201912146RA (enExample) |
| SI (1) | SI3638370T1 (enExample) |
| SM (1) | SMT202100037T1 (enExample) |
| WO (1) | WO2018229738A1 (enExample) |
| ZA (1) | ZA201908087B (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3091353A1 (en) | 2018-02-15 | 2019-08-22 | Intrabio Ltd | Therapeutic agents for treating restless legs syndrome |
| WO2020115715A1 (en) * | 2018-12-06 | 2020-06-11 | Intrabio Ltd. | Deuterated analogs of acetyl-leucine |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE8701662L (sv) * | 1987-04-22 | 1988-10-23 | Gelder Nico M Van | Saett och medel foer att behandla neurologiska sjukdomar, exempelvis migraen genom paaverkan av nervcellerna |
| US20040127501A1 (en) * | 2002-09-24 | 2004-07-01 | Zhengming Chen | Therapeutic agents useful for treating pain |
| US20060063827A1 (en) | 2004-09-23 | 2006-03-23 | Yu Ruey J | Systemic administration of therapeutic amino acids and N-acetylamino acids |
| MY142655A (en) * | 2003-06-12 | 2010-12-15 | Euro Celtique Sa | Therapeutic agents useful for treating pain |
| PT1641775E (pt) * | 2003-07-03 | 2009-04-23 | Euro Celtique Sa | Derivados de 2-piridina-alcino úteis para o tratamento da dor |
| ES2327684T3 (es) * | 2003-07-24 | 2009-11-02 | Euro-Celtique S.A. | Compuestos heteroaril-tetrahidropiridilo utiles para el tratamiento o la prevencion del dolor. |
| PL1664041T3 (pl) * | 2003-09-22 | 2008-12-31 | Euro Celtique Sa | Przydatne do leczenia bólu związki fenylowo-karboksyamidowe |
| PT1664016E (pt) * | 2003-09-22 | 2008-12-29 | Euro Celtique Sa | Agentes terapêuticos úteis para tratamento da dor |
| AP2006003678A0 (en) * | 2003-12-30 | 2006-08-31 | Euro Celtique Sa | Piperazines useful for treating pain |
| FR2905600B1 (fr) * | 2006-09-13 | 2010-01-15 | Pf Medicament | Traitement des vertiges par l'acetyl-l-leucine. |
| TN2010000251A1 (fr) | 2010-06-03 | 2011-11-11 | Rekik Raouf | N-acetyl-dl-leucine medicament neuro et retino protecteur |
| WO2011162409A1 (en) * | 2010-06-22 | 2011-12-29 | Shionogi & Co., Ltd. | Compounds having trpv1 antagonistic activity and uses thereof |
| LT2588130T (lt) | 2010-06-25 | 2016-12-12 | Shire Human Genetic Therapies, Inc. | Terapinės priemonės pristatymas cns |
| JP6092113B2 (ja) * | 2010-11-09 | 2017-03-08 | マンカインド コーポレイション | セロトニン受容体アゴニストおよびジケトピペラジンを含む偏頭痛治療のための組成物 |
| AU2012293417A1 (en) * | 2011-08-10 | 2013-05-02 | Purdue Pharma L.P. | TRPV1 antagonists including dihydroxy substituent and uses thereof |
| KR102413754B1 (ko) | 2016-04-19 | 2022-06-27 | 인트라바이오 리미티드 | 이동성 및 인지 기능을 개선시키기 위한 아세틸-류신 또는 이의 약제학적으로 허용되는 염 |
| MA55947A (fr) | 2016-08-11 | 2022-03-23 | Intrabio Ltd | Compositions pharmaceutiques et utilisations dirigées vers des troubles d'entreposage lysosomial |
| PL3416631T3 (pl) | 2016-08-11 | 2019-11-29 | Intrabio Ltd | Środki terapeutyczne do leczenia chorób neurodegeneracyjnych |
| PT3600276T (pt) | 2017-03-28 | 2023-07-11 | Intrabio Ltd | Beta-histina, ou um seu sal farmaceuticamente aceitável, e um inibidor da monoamina oxidase, para utilização no tratamento ou prevenção de um ou mais sintomas de vertigem num indivíduo |
| CN111542314B (zh) | 2017-10-18 | 2023-11-24 | 内在生物技术有限公司 | 神经退行性疾病的治疗剂 |
| US12458614B2 (en) | 2017-10-18 | 2025-11-04 | Intrabio Ltd | Therapeutic agents for improved mobility and cognitive function and for treating neurodegenerative diseases and lysosomal storage disorders |
| CA3091353A1 (en) | 2018-02-15 | 2019-08-22 | Intrabio Ltd | Therapeutic agents for treating restless legs syndrome |
| WO2020115715A1 (en) | 2018-12-06 | 2020-06-11 | Intrabio Ltd. | Deuterated analogs of acetyl-leucine |
| IL321899A (en) | 2019-03-02 | 2025-09-01 | Intrabio Ltd | Leucine, acetyl leucine and related analogs for the treatment of disease |
| EP4650003A2 (en) | 2019-06-28 | 2025-11-19 | IntraBio Ltd | Combination therapy with acetyl-leucine and miglustat for treating a lysosomal storage disease |
| US20230051742A1 (en) | 2020-01-13 | 2023-02-16 | Intrabio Ltd. | Treatment of late-onset neurodegenerative diseases in heterozygous npc1 gene mutation carriers |
-
2017
- 2017-06-14 GB GBGB1709459.0A patent/GB201709459D0/en not_active Ceased
-
2018
- 2018-06-25 AU AU2018284330A patent/AU2018284330B2/en active Active
- 2018-06-25 MD MDE20200433T patent/MD3638370T2/ro unknown
- 2018-06-25 PL PL18749124T patent/PL3638370T3/pl unknown
- 2018-06-25 HU HUE18749124A patent/HUE053089T2/hu unknown
- 2018-06-25 JP JP2020519196A patent/JP7130739B2/ja active Active
- 2018-06-25 WO PCT/IB2018/054676 patent/WO2018229738A1/en not_active Ceased
- 2018-06-25 ES ES18749124T patent/ES2847169T3/es active Active
- 2018-06-25 DK DK18749124.6T patent/DK3638370T3/da active
- 2018-06-25 SG SG11201912146RA patent/SG11201912146RA/en unknown
- 2018-06-25 SI SI201830195T patent/SI3638370T1/sl unknown
- 2018-06-25 PT PT187491246T patent/PT3638370T/pt unknown
- 2018-06-25 SM SM20210037T patent/SMT202100037T1/it unknown
- 2018-06-25 CN CN201880039532.2A patent/CN111093772B/zh active Active
- 2018-06-25 KR KR1020197038730A patent/KR102594130B1/ko active Active
- 2018-06-25 EP EP18749124.6A patent/EP3638370B1/en active Active
- 2018-06-25 IL IL271211A patent/IL271211B2/en unknown
- 2018-06-25 LT LTEP18749124.6T patent/LT3638370T/lt unknown
- 2018-06-25 RS RS20210046A patent/RS61481B1/sr unknown
- 2018-06-25 US US16/622,785 patent/US11471434B2/en active Active
- 2018-06-25 MX MX2019014784A patent/MX387909B/es unknown
- 2018-06-25 HR HRP20210108TT patent/HRP20210108T1/hr unknown
- 2018-06-25 MA MA49396A patent/MA49396B1/fr unknown
-
2019
- 2019-12-05 ZA ZA2019/08087A patent/ZA201908087B/en unknown
-
2021
- 2021-01-18 CY CY20211100033T patent/CY1123860T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101442997B (zh) | 雷沙吉兰用于治疗多动腿综合征 | |
| JP2022153638A5 (enExample) | ||
| JPWO2021250434A5 (enExample) | ||
| JP2023181322A (ja) | 睡眠時無呼吸を治療するための方法および組成物 | |
| JP2020516646A5 (enExample) | ||
| JP2023073373A5 (enExample) | ||
| JP2019516756A5 (enExample) | ||
| JP2020526575A5 (enExample) | ||
| JP2016505050A5 (enExample) | ||
| JPH06505994A (ja) | 光学的純粋（ｓ）メトプロロールを含む組成物及び方法 | |
| CN101610760A (zh) | 恶病质的治疗 | |
| Moore et al. | Management of Motor | |
| Sweet et al. | Methyldopa as an adjunct to levodopa treatment of Parkinson's disease | |
| JP7130739B2 (ja) | 片頭痛の治療 | |
| Penarrocha et al. | Cluster headache and cocaine use | |
| JPWO2021089678A5 (enExample) | ||
| JPWO2022045336A5 (enExample) | ||
| JP2015515971A5 (enExample) | ||
| JP7034314B2 (ja) | うつ病を予防または治療するための安息香酸またはその塩および誘導体 | |
| Calvo-Guirado et al. | Clinical Study of GG+ Analgesic and Anti-inflammatory Properties of Cannabis Derivatives in Patients with Cold and Heat Effects in Temporomandibular Joint Disorders: A Preliminary Study | |
| JPWO2020018291A5 (enExample) | ||
| JPWO2021038500A5 (enExample) | ||
| RU2312667C1 (ru) | Способ лечения побочных нейротоксических реакций, вызванных противотуберкулезными препаратами | |
| Feisal et al. | The efficacy of acupuncture in decreasing The Pittsburgh Sleep Quality Index scores of depressive patients with insomnia | |
| JP2008506630A (ja) | ゾルピデムの更なる治療的使用 |